JP2009530237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530237A5 JP2009530237A5 JP2008558793A JP2008558793A JP2009530237A5 JP 2009530237 A5 JP2009530237 A5 JP 2009530237A5 JP 2008558793 A JP2008558793 A JP 2008558793A JP 2008558793 A JP2008558793 A JP 2008558793A JP 2009530237 A5 JP2009530237 A5 JP 2009530237A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- pain
- alkyl
- quinazolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000002193 Pain Diseases 0.000 claims 8
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 230000036407 pain Effects 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- 206010013663 drug dependence Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- YONHKFQFURQDMK-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-(4-oxo-2-propan-2-ylquinazolin-3-yl)cyclopropane-1-carboxamide Chemical compound CC(C)C1=NC2=CC=CC=C2C(=O)N1NC(=O)C1CC1C1=CC=C(Cl)C=C1 YONHKFQFURQDMK-UHFFFAOYSA-N 0.000 claims 2
- QEAALOZBRNDKGH-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-(4-oxo-2-propan-2-ylquinazolin-3-yl)cyclopropane-1-carboxamide Chemical compound CC(C)C1=NC2=CC=CC=C2C(=O)N1NC(=O)C1CC1C1=CC=C(F)C=C1 QEAALOZBRNDKGH-UHFFFAOYSA-N 0.000 claims 2
- VPIBGRKWQBHUAU-UHFFFAOYSA-N 2-(4-methylphenyl)-n-(4-oxo-2-propan-2-ylquinazolin-3-yl)cyclopropane-1-carboxamide Chemical compound CC(C)C1=NC2=CC=CC=C2C(=O)N1NC(=O)C1CC1C1=CC=C(C)C=C1 VPIBGRKWQBHUAU-UHFFFAOYSA-N 0.000 claims 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 206010003441 asbestosis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- WNPJPUXCGCJIDY-UHFFFAOYSA-N 2-(3-fluoro-4-methylphenyl)-n-(4-oxo-2-propan-2-ylquinazolin-3-yl)cyclopropane-1-carboxamide Chemical compound CC(C)C1=NC2=CC=CC=C2C(=O)N1NC(=O)C1CC1C1=CC=C(C)C(F)=C1 WNPJPUXCGCJIDY-UHFFFAOYSA-N 0.000 claims 1
- KWNYJKVRMVUNFU-UHFFFAOYSA-N 2-(3-fluorophenyl)-n-(4-oxo-2-propan-2-ylquinazolin-3-yl)cyclopropane-1-carboxamide Chemical compound CC(C)C1=NC2=CC=CC=C2C(=O)N1NC(=O)C1CC1C1=CC=CC(F)=C1 KWNYJKVRMVUNFU-UHFFFAOYSA-N 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 229920000742 Cotton Polymers 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000028462 aluminosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 235000019504 cigarettes Nutrition 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000028329 epileptic seizure Diseases 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 230000030135 gastric motility Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 230000007074 memory dysfunction Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- WIDGAHYTBQLQDD-UHFFFAOYSA-N n-(4-oxo-2-propan-2-ylquinazolin-3-yl)-2-phenylcyclopropane-1-carboxamide Chemical compound CC(C)C1=NC2=CC=CC=C2C(=O)N1NC(=O)C1CC1C1=CC=CC=C1 WIDGAHYTBQLQDD-UHFFFAOYSA-N 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 206010035653 pneumoconiosis Diseases 0.000 claims 1
- 208000014321 polymorphic ventricular tachycardia Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010047302 ventricular tachycardia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200600368 | 2006-03-15 | ||
| US78252906P | 2006-03-16 | 2006-03-16 | |
| PCT/EP2007/052239 WO2007104717A1 (en) | 2006-03-15 | 2007-03-09 | Quinazolinones and their use as potassium channels activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009530237A JP2009530237A (ja) | 2009-08-27 |
| JP2009530237A5 true JP2009530237A5 (enExample) | 2010-04-22 |
Family
ID=38042515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008558793A Pending JP2009530237A (ja) | 2006-03-15 | 2007-03-09 | キナゾリノン及びカリウムチャネル活性化剤としてのその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090036473A1 (enExample) |
| EP (1) | EP1996560A1 (enExample) |
| JP (1) | JP2009530237A (enExample) |
| WO (1) | WO2007104717A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8178544B2 (en) | 2007-05-23 | 2012-05-15 | Neurosearch A/S | 2, 3-diamino-quinazolinone derivatives and their medical use |
| US20110269783A1 (en) * | 2008-11-10 | 2011-11-03 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| US20130184294A1 (en) * | 2010-09-21 | 2013-07-18 | Pfizer Inc. | Pyrimidones for Treatment of Potassium Channel Related Diseases |
| WO2013067591A1 (en) * | 2011-11-10 | 2013-05-16 | Relevare Australia Pty Ltd | Topical formulations for pain management |
| US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| JP7050797B2 (ja) | 2016-10-25 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 |
| WO2018095877A1 (en) | 2016-11-28 | 2018-05-31 | Boehringer Ingelheim International Gmbh | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10253004B2 (en) | 2017-01-26 | 2019-04-09 | Boehringer Ingelheim International Gmbh | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7050791B2 (ja) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| CN110248929B (zh) | 2017-01-26 | 2023-05-12 | 勃林格殷格翰国际有限公司 | 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| CN110312714B (zh) | 2017-01-26 | 2022-12-09 | 勃林格殷格翰国际有限公司 | 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| JP7023969B2 (ja) | 2017-01-26 | 2022-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP7121144B2 (ja) * | 2018-02-20 | 2022-08-17 | ハー・ルンドベック・アクチエゼルスカベット | Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体 |
| US10590067B2 (en) | 2018-02-20 | 2020-03-17 | H. Lundbeck A/S | Alcohol derivatives of carboxamides as Kv7 potassium channel openers |
| JP7720829B2 (ja) * | 2019-08-02 | 2025-08-08 | ハー・ルンドベック・アクチエゼルスカベット | Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体 |
| CN119490430A (zh) | 2019-08-02 | 2025-02-21 | H.隆德贝克有限公司 | 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物 |
| AR119521A1 (es) | 2019-08-02 | 2021-12-22 | H Lundbeck As | DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7 |
| US11352366B2 (en) | 2019-08-30 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | 2-aminoquinazolinone derivative |
| CN114650986A (zh) * | 2019-08-30 | 2022-06-21 | 住友制药株式会社 | 2-氨基喹唑啉酮衍生物 |
| CN117304065A (zh) * | 2022-06-17 | 2023-12-29 | 上海雨程生物科技有限公司 | 芳基环丙基类化合物制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295781A1 (en) * | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | Arylcyclopropylcarboxylic amides as potassium channel openers |
| EP1663237B1 (en) * | 2003-09-10 | 2013-06-19 | Icagen, Inc. | Fused ring heterocycles as potassium channel modulators |
-
2007
- 2007-03-09 US US12/278,091 patent/US20090036473A1/en not_active Abandoned
- 2007-03-09 WO PCT/EP2007/052239 patent/WO2007104717A1/en not_active Ceased
- 2007-03-09 EP EP07726760A patent/EP1996560A1/en not_active Withdrawn
- 2007-03-09 JP JP2008558793A patent/JP2009530237A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6155280B2 (ja) | フェニルアルキルカルバメート誘導体化合物およびこれを含む薬学組成物 | |
| JP2009510044A5 (enExample) | ||
| RU2009147708A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842 | |
| JP2013519685A (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 | |
| JP2009509921A5 (enExample) | ||
| JP2018058890A5 (enExample) | ||
| CA2606087A1 (en) | Novel oxadiazole derivatives and their medical use | |
| JP2012532107A5 (enExample) | ||
| JP2009530237A (ja) | キナゾリノン及びカリウムチャネル活性化剤としてのその使用 | |
| ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| JP2013526615A5 (enExample) | ||
| WO2012009258A3 (en) | Peptidomimetic galanin receptor modulators | |
| US11377436B2 (en) | EAAT2 enhancing molecules | |
| JP2010522709A5 (enExample) | ||
| JP2013510178A (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのアリールおよびヘテロアリールスルホン、組成物、および神経機能不全を治療する方法 | |
| CA2669915A1 (en) | Substituted bicyclocarboxyamide compounds | |
| US11648253B2 (en) | Thienopyrimidinone NMDA receptor modulators and uses thereof | |
| JP2013544277A5 (enExample) | ||
| JP2019501979A (ja) | Ｅａａｔ２活性化剤としてのピリダジン誘導体 | |
| MX2019002444A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| JP2008530171A5 (enExample) | ||
| TW200744576A (en) | Propargylated aminoindans, processes for preparation, and uses thereof | |
| JP2017538753A5 (enExample) | ||
| JP2014518552A5 (enExample) | ||
| JP2015521643A5 (enExample) |